RBC Capital Downgrades Endologix (ELGX) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Endologix Reports Results for the Second Quarter 2016
August 2, 2016 4:06 PM EDTIRVINE, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ: ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2016.
John McDermott, Endologix Chairman and Chief Executive Officer, said, We continue to deliver solid revenue growth above expectations and are very pleased with the TriVascular merger integration. Our revenue performance in the second quarter was driven by strong growth with... More
